July 25th 2024
The organization is poised to lobby for an indefinite extension of Medicare reimbursement for telemedicine services and fight the December 31, 2024, sunset date when Medicare plans to cease reimbursement for these services.
The Ins and Outs of Lubricating Eye Drops
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
Modern-izing Retina
September 4 - 5, 2024
View More
Medical Crossfire®: Expert Insights in Anti-VEGF Dosing for nAMD and DME – Optimizing Reduction in Treatment Burden
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (CME Credit)
View More
Community Practice Connections™: Novel Treatment Strategies in the Management of nAMD & DME - Lessons from Clinical Trial and Real-World Data
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (COPE Credit)
View More
EyeCon 2024
September 27-28, 2024
Register Now!
Join us after AAO for a CME session | In-Person + Virtual
October 19, 2024
Register Now!
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Advancing Treatment in Neovascular Retinal Disease with Novel Therapies: Insights and Strategies from Latest Real-World and Clinical Data
View More
Rapid Reviews in Retina™: Emerging Updates from Fall 2023 – Addressing the Wealth of New Data in Treatments for nAMD and DME
View More
(CME) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(CME) Stratifying the Spectrum of Care in Glaucoma Management – Advancing Treatment with a Vast Armamentarium
View More
(COPE) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(COPE) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(CME) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(COPE) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(CME) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)
View More
SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management
View More
Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
View More
Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (CME Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
World Sight Day 2023: Focusing on preservation of vision in the workplace
October 11th 2023World Sight Day on October 12 highlights the vital role of eye care in workplaces. The International Agency for the Prevention of Blindness urges employers to prioritize eye health, aiming to enhance well-being, safety, and productivity.
EURETINA 2023: Safety and efficacy through week 48 in the Phase 2a STARLIGHT clinical trial
October 6th 2023We spoke with Michael Singer, MD who provided an overview of his presentation and his work with Nanoscope Therapeutics, "MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial."
Patients and their eye health: Experts weigh in
September 27th 2023We spoke with researchers and industry professionals at the 2023 ASRS meeting in Seattle, Washington. We asked them, "What do you wish patients knew about eye health?" Here's what Michael Ip, MD, Shawn Kavoussi, MD, and Megan Baldwin, PhD, had to say!
Ocugen announces positive clinical study update from the phase 1/2 trial of OCU400
September 15th 2023According to the company, the clinical study update suggests continued positive trends in best-corrected visual acuity and multi-luminance mobility testing as well as positive trends in low-luminance visual acuity among treated eyes.
What retina specialists want you to know about neovascular AMD and DME therapies: 10 top takeaways
September 15th 2023A panel of esteemed retina specialists recently delved into innovative therapies for neovascular age-related macular degeneration and diabetic macular edema, focusing on personalized treatment, telemedicine, and the ongoing quest for advancements.
OWL Leadership Summit 2023: Navigating ophthalmic leadership challenges and embracing diversity
September 14th 2023The Ophthalmic World Leaders (OWL) Leadership Summit, scheduled for September 21 and 22, 2023, in Austin, Texas, will feature a lineup of prominent speakers and engaging discussions on a wide range of leadership topics and industry insights.
Opus Genetics doses first patient in Phase 1/2 trial of OPGx-LCA5 in patients diagnosed with LCA5
September 12th 2023According to the company, OPGx-LCA5 is designed to address vision loss due to Leber congenital amaurosis associated with mutations in the LCA5 gene, which causes one of the most severe early-onset retinal dystrophies.